Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-PaclitaxelNeha Papneja, Shahid Ahmed, Adnan Zaidi et al.|Pancreas|2019Cited by 49
Primary tumor location and survival in general population with metastatic colorectal cancer (mCRC).Shahid Ahmed, Nayyer Iqbal, Riaz Alvi et al.|Journal of Clinical Oncology|2017Cited by 1
Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experienceNeha Papneja, Petr Kavan, Shahid Ahmed et al.|Annals of Oncology|2019Cited by 1
Time to first-line chemotherapy and travel distance to the cancer center and their relationship to subsequent-line therapies in stage IV CRC.Mahjabeen Fatima Iqbal, Shahid Ahmed, Aleksi Suo et al.|Journal of Clinical Oncology|2016Cited by 0
First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.Ivan Barrera, Petr Kavan, Neha Papneja et al.|Journal of Clinical Oncology|2020Cited by 0